Merck & Co., Inc. in 4 stories
The narratives MRK currently appears in, with its side and exposure in each.
Bull side
2 stories- GLP-1 Eats Everything
MRK in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Merck's oral GLP-1 and broader cardiometabolic pipeline gives it a path to participate in the expanding obesity-drug market.
- China Becomes Pharma's Global R&D Engine
MRK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Merck can use China-sourced combinations and next-generation mechanisms to extend its oncology franchise beyond Keytruda.
Bear side
2 stories- America Imports the World's Drug Prices
MRK in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Reference pricing threatens the long-duration cash flows attached to Keytruda and Merck's next generation of patented medicines.
- The Patent Cliff Sparks a Biotech Land Grab
MRK in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Merck must replace an exceptionally large Keytruda revenue base as its principal patents approach expiration.